The above data suggest promising therapeutic potential of DPP4 inhibitors in the treatment of AD through the targeting of core pathological features such as Aβ production, tau hyperphosphorylation, synaptic loss, and neuroinflammation. The gene discussed is MAPT; the disease is Alzheimer disease.